RXRX logo

RXRX Cash from investing

annual CFI:

$260.06M+$270.29M(+2642.62%)
December 31, 2024

Summary

  • As of today (September 18, 2025), RXRX annual cash flow from investing activities is $260.06 million, with the most recent change of +$270.29 million (+2642.62%) on December 31, 2024.
  • During the last 3 years, RXRX annual CFI has risen by +$531.80 million (+195.70%).
  • RXRX annual CFI is now at all-time high.

Performance

RXRX Cash from investing Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherRXRXcash flow metrics

quarterly CFI:

-$5.81M+$1.46M(+20.11%)
June 30, 2025

Summary

  • As of today (September 18, 2025), RXRX quarterly cash flow from investing activities is -$5.81 million, with the most recent change of +$1.46 million (+20.11%) on June 30, 2025.
  • Over the past year, RXRX quarterly CFI has dropped by -$1.63 million (-38.88%).
  • RXRX quarterly CFI is now -102.11% below its all-time high of $275.46 million, reached on December 31, 2024.

Performance

RXRX quarterly CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherRXRXcash flow metrics

TTM CFI:

$257.82M-$1.63M(-0.63%)
June 30, 2025

Summary

  • As of today (September 18, 2025), RXRX TTM cash flow from investing activities is $257.82 million, with the most recent change of -$1.63 million (-0.63%) on June 30, 2025.
  • Over the past year, RXRX TTM CFI has increased by +$271.49 million (+1986.00%).
  • RXRX TTM CFI is now -0.86% below its all-time high of $260.06 million, reached on December 31, 2024.

Performance

RXRX TTM CFI Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherRXRXcash flow metrics

Cash from investing Formula

CFI = Cash Inflows from Investments − Cash Outflows for Investments

RXRX Cash from investing Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+2642.6%-38.9%+1986.0%
3 y3 years+195.7%-217.6%+363.4%
5 y5 years+6751.1%-10000.0%+10000.0%

RXRX Cash from investing Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-yearat high+195.7%-102.1%+27.2%-0.9%+363.4%
5 y5-yearat high+195.7%-102.1%+97.0%-0.9%+194.9%
alltimeall timeat high+195.7%-102.1%+97.0%-0.9%+194.9%

RXRX Cash from investing History

DateAnnualQuarterlyTTM
Jun 2025
-
-$5.81M(-20.1%)
$257.82M(-0.6%)
Mar 2025
-
-$7.27M(-102.6%)
$259.44M(-0.2%)
Dec 2024
$260.06M(-2642.6%)
$275.46M(-6138.1%)
$260.06M(-1554.1%)
Sep 2024
-
-$4.56M(+9.1%)
-$17.89M(+30.8%)
Jun 2024
-
-$4.18M(-37.1%)
-$13.67M(+18.4%)
Mar 2024
-
-$6.65M(+167.4%)
-$11.54M(+12.8%)
Dec 2023
-$10.23M(-105.3%)
-$2.49M(+617.0%)
-$10.23M(-34.9%)
Sep 2023
-
-$347.00K(-83.1%)
-$15.72M(-141.8%)
Jun 2023
-
-$2.05M(-61.6%)
$37.61M(-15.7%)
Mar 2023
-
-$5.34M(-33.1%)
$44.60M(-76.9%)
Dec 2022
$193.25M
-$7.98M(-115.1%)
$193.25M(+29.7%)
Sep 2022
-
$52.98M(+972.6%)
$148.99M(-252.2%)
DateAnnualQuarterlyTTM
Jun 2022
-
$4.94M(-96.6%)
-$97.87M(-10.2%)
Mar 2022
-
$143.30M(-374.3%)
-$109.02M(-59.9%)
Dec 2021
-$271.74M(+3009.2%)
-$52.24M(-73.1%)
-$271.74M(+21.3%)
Sep 2021
-
-$193.87M(+3020.9%)
-$224.09M(+566.0%)
Jun 2021
-
-$6.21M(-68.0%)
-$33.65M(+22.5%)
Mar 2021
-
-$19.42M(+322.9%)
-$27.47M(+214.3%)
Dec 2020
-$8.74M(+123.5%)
-
-
Dec 2020
-
-$4.59M(+34.0%)
-$8.74M(+110.7%)
Sep 2020
-
-$3.43M(+8684.6%)
-$4.15M(+473.9%)
Jun 2020
-
-$39.00K(-94.3%)
-$723.00K(+5.7%)
Mar 2020
-
-$684.00K
-$684.00K
Dec 2019
-$3.91M
-
-

FAQ

  • What is Recursion Pharmaceuticals, Inc. annual cash flow from investing activities?
  • What is the all time high annual CFI for Recursion Pharmaceuticals, Inc.?
  • What is Recursion Pharmaceuticals, Inc. annual CFI year-on-year change?
  • What is Recursion Pharmaceuticals, Inc. quarterly cash flow from investing activities?
  • What is the all time high quarterly CFI for Recursion Pharmaceuticals, Inc.?
  • What is Recursion Pharmaceuticals, Inc. quarterly CFI year-on-year change?
  • What is Recursion Pharmaceuticals, Inc. TTM cash flow from investing activities?
  • What is the all time high TTM CFI for Recursion Pharmaceuticals, Inc.?
  • What is Recursion Pharmaceuticals, Inc. TTM CFI year-on-year change?

What is Recursion Pharmaceuticals, Inc. annual cash flow from investing activities?

The current annual CFI of RXRX is $260.06M

What is the all time high annual CFI for Recursion Pharmaceuticals, Inc.?

Recursion Pharmaceuticals, Inc. all-time high annual cash flow from investing activities is $260.06M

What is Recursion Pharmaceuticals, Inc. annual CFI year-on-year change?

Over the past year, RXRX annual cash flow from investing activities has changed by +$270.29M (+2642.62%)

What is Recursion Pharmaceuticals, Inc. quarterly cash flow from investing activities?

The current quarterly CFI of RXRX is -$5.81M

What is the all time high quarterly CFI for Recursion Pharmaceuticals, Inc.?

Recursion Pharmaceuticals, Inc. all-time high quarterly cash flow from investing activities is $275.46M

What is Recursion Pharmaceuticals, Inc. quarterly CFI year-on-year change?

Over the past year, RXRX quarterly cash flow from investing activities has changed by -$1.63M (-38.88%)

What is Recursion Pharmaceuticals, Inc. TTM cash flow from investing activities?

The current TTM CFI of RXRX is $257.82M

What is the all time high TTM CFI for Recursion Pharmaceuticals, Inc.?

Recursion Pharmaceuticals, Inc. all-time high TTM cash flow from investing activities is $260.06M

What is Recursion Pharmaceuticals, Inc. TTM CFI year-on-year change?

Over the past year, RXRX TTM cash flow from investing activities has changed by +$271.49M (+1986.00%)
On this page